Cooper Companies stock sinks to near 52-week low after second guidance cut in three months

Shares of the Cooper Companies, the medical device maker behind CooperVision contact lenses and the CooperSurgical fertility business, closed the week at $53.91, near a 52-week low, after the company cut its annual sales forecast for the second time in three months and its board walked away from a sale of the surgical unit that investors had been counting on. The stock is down roughly 20 percent since Cooper reported fiscal third-quarter results on September 9, erasing several billion dollars of market value in two trading sessions.

The San Ramon, California-based company beat Wall Street on profit but missed on revenue, and its forecast for the current quarter came in well short of what analysts had modeled. Within a day, at least three plaintiffs' law firms said they were investigating whether Cooper's public statements about demand for its lenses had been misleading, and several Wall Street analysts cut both their ratings and price targets on the stock.

The numbers behind the selloff

Cooper's fiscal third quarter, which ended July 31, produced revenue of $1.066 billion, up about 1 percent from a year earlier and short of the roughly $1.1 billion analysts had expected. Non-GAAP earnings of $1.15 a share beat the $1.12 consensus estimate, and GAAP earnings of $2.24 a share were inflated by a one-time $307.2 million tax benefit tied to the resolution of a U.K. tax examination.

It was the outlook, not the quarter itself, that rattled investors. Cooper told analysts to expect fourth-quarter adjusted earnings of $1.05 to $1.09 a share, versus a Street estimate of $1.19, on revenue of $1.057 billion to $1.080 billion, versus an expected $1.11 billion. For the full fiscal year, the company now sees revenue of $4.229 billion to $4.252 billion and non-GAAP earnings of $4.51 to $4.55 a share — both below what analysts had penciled in.

The reversal has been sharp. In first-quarter results issued on March 5, Cooper raised its full-year forecast for organic growth at CooperVision, its largest division, to a range of 4.5 percent to 5.5 percent. By its second-quarter report in June, weak demand in Japan and China had pulled that guidance down to 3.5 percent to 4.5 percent. On September 9, the company cut it again, to just 1 percent to 2 percent for the year, implying the division's sales will shrink by roughly 1 percent in the current quarter.

Destocking, not demand, the company says

Chief Executive Al White told analysts on the earnings call that the shortfall was not a sign of weaker consumer demand but of distributors working down their own contact-lens inventories, particularly of the Biofinity line, daily disposables and older hydrogel products. Asked directly whether the entire guidance cut was attributable to that channel destocking rather than any drop-off in usage, White said plainly: "It's all destocking." He said underlying U.S. consumption had held in the mid-single digits all year and that the company expected the inventory drawdown to run its course by the end of the fiscal fourth quarter, with a return to more normal growth in 2027.

That explanation did little to calm the stock. Shares fell roughly 15 percent in after-hours trading Wednesday night, then dropped as much as 17.8 percent intraday on Thursday before closing that session at $54.17, down 14.7 percent. The stock drifted slightly lower again on Friday, September 11, to end the week at $53.91 — close to the 52-week low of $51.01 and far from the 52-week high of $89.83. Cooper's market capitalization stood at roughly $10.25 billion at Friday's close, down by an estimated $2.6 billion to $2.7 billion from before the earnings report, based on the change in share price.

A sale considered, then rejected

The guidance cut landed alongside a second, separate announcement: the conclusion of a strategic review Cooper's board launched in December 2025 to examine, among other things, a possible sale of CooperSurgical, the roughly $1.4 billion-a-year unit that makes fertility, obstetrics and gynecological products including the Paragard copper IUD. After what the company described as a review involving numerous interested parties, the board unanimously decided against a sale, concluding that outside offers undervalued the business.

"Our fiduciary duty is to maximize shareholder value, and the Board is collectively aligned that given the offers received, retaining CooperSurgical is the best path forward to creating shareholder value at this time," said Colleen Jay, chair of Cooper's board.

The board pointed to two developments it said had temporarily depressed the bids: a $271.6 million net settlement reached this year over lawsuits alleging embryo loss linked to a 2023 recall of CooperSurgical's LifeGlobal embryo culture media, and the arrival of a new rival to Paragard, which for nearly four decades had been the only non-hormonal IUD sold in the United States. The Food and Drug Administration approved Miudella, a copper IUD from Sebela Women's Health, in February 2025, ending Paragard's decades-long exclusivity in that category. Instead of selling the unit, Cooper's board expanded the company's share buyback authorization by $1 billion, to $3 billion in total.

Wall Street and law firms respond

Analysts moved quickly to mark down their expectations. Baird's Jeff Johnson downgraded the stock to Neutral from Outperform and cut his price target to $61 from $85; BofA Securities' Craig Bijou moved to Neutral from Buy and lowered his target to $65 from $80; and William Blair shifted its rating to Market Perform from Outperform. The common thread in the notes, according to coverage of the reaction, was skepticism that channel destocking alone explained both the magnitude of the miss and the timing, coming only three months after management had reaffirmed its confidence in the prior forecast.

That skepticism has attracted legal scrutiny. The Law Offices of Frank R. Cruz, the Law Offices of Howard G. Smith, and Levi & Korsinsky each announced they were investigating potential securities-fraud claims against Cooper on behalf of shareholders who bought stock between the March guidance raise and the September disclosure. Levi & Korsinsky's notice to investors said the firm was examining whether Cooper made materially false or misleading statements about CooperVision's growth outlook and the state of its U.S. distribution channel before the stock's decline. Such investigation notices are a routine precursor to securities class actions and do not necessarily result in litigation; no lawsuit had been filed as of Friday.

Shareholders bear the most immediate cost, having watched roughly a fifth of the stock's value disappear in a week, but the ripple effects extend further. CooperVision's independent optometrists and retail partners are absorbing the inventory correction Cooper says is driving the miss, and the CooperSurgical decision leaves fertility clinics and hospital systems that rely on its embryology and IUD products with continuity of ownership rather than the uncertainty a sale would have introduced, at least for now.

What happens next

Cooper's next scheduled test is its fiscal fourth-quarter and full-year report, expected in December, when management will need to show that the channel destocking it has repeatedly cited has in fact ended and that CooperVision's growth trajectory is stabilizing rather than continuing to erode. The company's expanded $3 billion buyback authorization gives it a tool to support the stock price in the meantime, though it does not address the underlying growth questions analysts have raised. The shareholder investigations remain in an early, fact-gathering stage, and it is not yet clear whether any will mature into formal litigation. For now, Cooper remains structured exactly as it was before the board opened the strategic review nine months ago — an outcome that satisfied neither the arbitrageurs who had bet on a sale nor the analysts who had hoped a cleaner, smaller company might justify a higher multiple.